NCT05600218

RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

Real World Andalusian Multicenter Data on Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Hospital Costa del Sol · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021. The aim of this study answer the following questions: * Changes in the mortality risk profile of these patients after treatment administration. * Baseline characteristics of patients initiating Selexipag. * Parameters used for risk stratification prior to treatment escalation. * Events during follow-up. No comparison group available

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	No intervention - Observational study	Real life drug evaluation

Timeline

• Start date: 2021-06-01
• Primary completion: 2023-12-31
• Completion: 2024-12-31
• First posted: 2022-10-31
• Last updated: 2022-11-07

Locations

10 sites across 1 country: Spain

Regulatory

• FDA-regulated drug study